Clinical features and prognostic implications of ecotropic viral integration site 1 (EVI1) in childhood acute lymphoblastic leukemia

References

• Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565. doi:10.1200/JCO.2010.30.7405.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):52–63. doi:10.1053/j.seminhematol.2008.09.007.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178. doi:10.1056/NEJMra052603.
   PubMed Web of Science ®Google Scholar
• Mucenski ML, Taylor BA, Ihle JN, et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol. 1988;8(1):301–308. doi:10.1128/mcb.8.1.301-308.1988.
   PubMed Web of Science ®Google Scholar
• Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11(12):2022–2031. doi:10.1038/sj.leu.2400880.
   PubMed Web of Science ®Google Scholar
• Yuasa H, Oike Y, Iwama A, et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. Embo J. 2005;24(11):1976–1987. doi:10.1038/sj.emboj.7600679.
   PubMed Web of Science ®Google Scholar
• Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis. 2008;40(2):141–147. doi:10.1016/j.bcmd.2007.07.012.
   PubMed Web of Science ®Google Scholar
• Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA. 1992;89(9):3937–3941. doi:10.1073/pnas.89.9.3937.
   PubMed Web of Science ®Google Scholar
• Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood. 1994;84(4):1243–1248.
   PubMed Web of Science ®Google Scholar
• Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329–4337. doi:10.1182/blood-2007-10-119230.
   PubMed Web of Science ®Google Scholar
• Gröschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. JCO. 2010;28(12):2101–2107. doi:10.1200/JCO.2009.26.0646.
   PubMed Web of Science ®Google Scholar
• Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101(3):837–845. doi:10.1182/blood-2002-05-1459.
   PubMed Web of Science ®Google Scholar
• Santamaría CM, Chillón MC, García-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood. 2009;114(1):148–152. doi:10.1182/blood-2008-11-187724.
   PubMed Web of Science ®Google Scholar
• Haas K, Kundi M, Sperr WR, et al. Expression and prognostic significance of different mRNA 5’-end variants of the oncogene EVI1 in 266 patients with de novo AML:EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer. 2008;47(4):288–298. doi:10.1002/gcc.20532.
   PubMed Web of Science ®Google Scholar
• Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118(4):1069–1076. doi:10.1182/blood-2011-02-334748.
   PubMed Web of Science ®Google Scholar
• Liao C, Xu X, Shen D, et al. Minimal residual disease-guided risk restratification and therapy improves the survival of childhood acute lymphoblastic leukemia: experience from a tertiary children’s hospital in China. J Pediatr Hematol Oncol. 2019;41(6):e346–e354. doi:10.1097/MPH.0000000000001412.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Jia M, Hu BF, Xu XJ, Zhang JY, Li SS, Tang YM. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: a single-center retrospective study of 837 patients from China. Curr Probl Cancer. 2021;45(6):100758–100768. doi:10.1016/j.currproblcancer.2021.100758.
   PubMed Web of Science ®Google Scholar
• Kilbey A, Stephens V, Bartholomew C. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth Differ. 1999;10(9):601–610.
   PubMedGoogle Scholar
• Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3(2):207–220. doi:10.1016/j.stem.2008.06.002.
   PubMed Web of Science ®Google Scholar
• Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942–949. doi:10.1038/leu.2010.47.
   PubMed Web of Science ®Google Scholar
• Ho PA, Alonzo TA, Gerbing RB, et al. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children’s oncology group. Br J Haematol. 2013;162(5):670–677. doi:10.1111/bjh.12444.
   PubMed Web of Science ®Google Scholar
• Konantz M, André MC, Ebinger M, et al. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia. 2013;27(1):56–65. doi:10.1038/leu.2012.211.
   PubMed Web of Science ®Google Scholar
• Su G, Lian X, Tan D, et al. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(2):472–479. doi:10.3109/10428194.2014.924118.
   PubMed Web of Science ®Google Scholar
• De Weer A, Poppe B, Cauwelier B, et al. Screening for EVI1: ectopic expression absent in T-cell acute lymphoblastic leukemia patients and cell lines. Cancer Genet Cytogenet. 2006;171(1):79–80. doi:10.1016/j.cancergencyto.2006.07.004.
   PubMedGoogle Scholar
• Gröschel S, Schlenk RF, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. JCO. 2013;31(1):95–103. doi:10.1200/JCO.2011.41.5505.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16(4):465–474. doi:10.1016/S1470-2045(15)70082-3.
   PubMed Web of Science ®Google Scholar